- Home
- OPRX vs GOSS Comparison
OPRX vs GOSS Comparison
Compare OPRX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | GOSS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 97.5M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OPRX | GOSS |
|---|---|---|
| Price | $8.06 | $0.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $16.67 | $4.19 |
| AVG Volume (30 Days) | 238.0K | ★ 27.0M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | $48,471,000.00 |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $8.34 | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $0.11 |
| 52 Week High | $22.25 | $3.87 |
Technical Indicators
Market Signals| Indicator | OPRX | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 64.32 | 46.29 |
| Support Level | $7.80 | $0.16 |
| Resistance Level | $8.26 | $0.20 |
| Average True Range (ATR) | 0.58 | 0.01 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 64.90 | 43.03 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).